Pain Medicine, Interventional Pain Medicine · Dalton, GA
NPI
1861750028
Since 2012
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
1504 N Thornton Ave Ste 103
Dalton, GA, 30720
Phone (770) 962-3642
Groups this clinician bills Medicare through
Medicare paid, 2024
$165K
2,476 services
Medicare patients, 2024
331
Average age 65
Drug cost, 2024
$996K
10,530 prescriptions
Company payments, 2025
$1,047
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amit Patel was code 99213 (office e&m - established), 941 times for 263 patients. In total Amit Patel billed 2,476 services in 43 codes, and Medicare paid $165K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 941 | 263 | $56.17 | $53K |
| 80305 Drug Tests | Office | 344 | 200 | $12.24 | $4,211 |
| 99214 Office E&M - Established | Office | 319 | 178 | $82.14 | $26K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 168 | 131 | $110.92 | $19K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 99 | 31 | $44.39 | $4,395 |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 82 | 73 | $151.27 | $12K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 60 | 20 | $34.25 | $2,055 |
| 99203 Office E&M - New | Office | 42 | 42 | $66.57 | $2,796 |
| 64635 Destruction by Neurolytic Agent - Back | Facility | 36 | 33 | $196.85 | $7,087 |
| 64636 Destruction by Neurolytic Agent - Back | Facility | 35 | 32 | $59.97 | $2,099 |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 31 | 30 | $194.77 | $6,038 |
| 77002 Imaging - Miscellaneous | Facility | 29 | 24 | $17.05 | $494 |
| 20610 Joint Injection | Facility | 29 | 24 | $32.81 | $952 |
| 64494 Nerve Block Injection - Back | Facility | 28 | 21 | $50.95 | $1,427 |
| 64493 Nerve Block Injection - Back | Facility | 28 | 21 | $91.37 | $2,558 |
By year: 2022 $283K for 3,883 services; 2023 $217K for 2,972 services; 2024 $165K for 2,476 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 344 | 200 | $12.24 | $4,211 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 168 | 131 | $110.92 | $19K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 82 | 73 | $151.27 | $12K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 31 | 30 | $194.77 | $6,038 |
Medicare prescription drug claims, 2024
In 2024, the drug Amit Patel prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 2,201 prescriptions and refills. In total Amit Patel wrote 10,530 Medicare prescriptions that cost $996K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 2,201 | 2,201 | 403 | $55K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 2,052 | 2,052 | 387 | $134K |
| Oxycodone Hcl Generic | 797 | 797 | 157 | $13K |
| Pregabalin Generic | 780 | 781 | 170 | $8,999 |
| Gabapentin Generic | 766 | 792 | 300 | $8,696 |
| Tizanidine Hcl Generic | 518 | 531 | 227 | $6,465 |
| Belbuca Buprenorphine Hcl | 425 | 425 | 95 | $314K |
| Buprenorphine Generic | 336 | 336 | 107 | $92K |
| Cyclobenzaprine Hcl Generic | 275 | 278 | 115 | $2,078 |
| Morphine Sulfate Er Morphine Sulfate | 221 | 221 | 41 | $4,069 |
| Tramadol Hcl Generic | 196 | 196 | 72 | $1,569 |
| Diclofenac Sodium Generic | 187 | 206 | 84 | $16K |
| Methocarbamol Generic | 127 | 129 | 56 | $1,461 |
| Baclofen Generic | 114 | 122 | 48 | $1,147 |
| Celecoxib Generic | 104 | 104 | 44 | $1,610 |
Brand drugs: 954 claims; generic drugs: 9,576 claims; opioid claims: 6,623.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amit Patel $1,047 ($1,047 in general payments such as food, travel and fees) from 9 companies. The largest payer was Salix Pharmaceuticals, a division of Bausch Health US, LLC with $646.
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 59 | $646 |
| Medtronic, Inc. MDT | 1 | $93.93 |
| Curonix LLC | 3 | $78.17 |
| Collegium Pharmaceutical, Inc. COLL | 4 | $74.38 |
| Gilead Sciences, Inc. GILD | 3 | $48.29 |
| Spinal Simplicity, LLC | 1 | $43.74 |
| Djo, LLC ENOV | 1 | $25.92 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $23.31 |
| Protega Pharmaceutials Inc | 1 | $13.54 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.